A retrospective cohort study reported that CAR-HEMATOTOX can predict severe cytopenia risk after CAR-T therapy by estimating the likelihood of grade 3–4 neutropenia and thrombocytopenia. The analysis included 96 patients and found higher-risk categories had dramatically elevated rates of both complications. Researchers framed the tool as an actionable way to anticipate hematologic adverse events that drive treatment interruptions, supportive care intensity and potential morbidity. The work also ties risk prediction to observable lab patterns after infusion. While the study design is retrospective, the headline value for translational teams is practical: a measurable score that can be integrated into post-infusion monitoring strategies. For cell therapy programs, improved early identification of hematologic toxicity can help optimize prophylaxis and inpatient resource allocation, which is particularly relevant as CAR-T expands into broader indications.